The Myeloma Drug Tracker shows where drugs are in the clinical trial pathway as potential treatments for myeloma. Available drugs are ones which have already been licensed for use in myeloma.
Using the filters below, you can explore the drug types and trial stages. Clicking on a drug will provide additional information and you can download an Infosheet if there is one available.
Further information can be found on our website under Clinical Trials and Novel Drugs.
Filter by drug type
13 Immunotherapy
6 Epigenetic Drug
3 Proteasome Inhibitor
7 Cell Signalling/Cycle
Filter by trial stage
Order by
Drug name
Drugs in Phase I
I
Drugs in Phase II
II
Drugs in Phase III
III
Available Drugs
A
Other | Drugs in Phase I
Uproleselan is a new drug being tested for myeloma. Uprolselan is thought to improve the overall impact of myeloma treatment by reducing the number of myeloma cells sticking to bone marrow through the inhibition of E-selectin. E-selectin is a type of a cell adhesion molecule which is involved in the binding of myeloma cells to bone marrow.
Other | Drugs in Phase I
s55746 is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as BCL-2 inhibitors, which work by accelerating cancer cell death.
Epigenetic Drug | Drugs in Phase I
CXD101 is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
Other | Drugs in Phase I
CC-92480 is a new drug being invesitgated as a treatment for myeloma. It is a cereblon E3 ubiquitin ligase modulating drug (CELMoD®).
Cell Signalling/Cycle | Drugs in Phase II
KW-2478 is a new drug being investigated as a treatment for myeloma in combination with other drugs. It is a heat shock protein 90 (HSP90) inhibitor that can prevent the growth of myeloma cells.
Other | Available Drugs
Pamidronate, also known as Aredia® is used in the treatment and prevention of myeloma bone disease. It belongs to a class of drug known as bisphosphonates.
Immunotherapy | Drugs in Phase II
AUTO2 is a new treatment being investigated in myeloma. It belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. CAR-T cells are immune cells (T-cells), taken from the patient, which are genetically engineered to recognise myeloma cells more easily. AUTO2 is the first dual targeting CAR-T cell therapy, as it is designed to target 2 proteins found on the surface of myeloma cells; B-cell maturation antigen (BCMA) and transmembrane activator, calcium modulator and cyclophilin ligand interactor (TACI). AUTO2 attaches to the proteins then removes and destroys the myeloma cells.
Cell Signalling/Cycle | Drugs in Phase I
AZD4573 is a new drug being investigated as a treatment for myeloma and other haematological malignancies. It is a cyclin dependent kinase 9 (CDK9) inhibitor.
Epigenetic Drug | Drugs in Phase I
RO6870810 is a drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as BET protein bromodomain inhibitors and works by interfering with the structure of DNA, leading to cell death.
Immunotherapy | Drugs in Phase II
Silituximab is a drug being investigated as a treatment for myeloma and high-risk smouldering myeloma. It belongs to a class of drugs known as monoclonal antibodies and specifically targets interleukin-6.
Epigenetic Drug | Drugs in Phase I
GSK525762 is a new drug being investigated as a treatment for myeloma. It belongs to a novel class of drugs called BET protein bromodomain inhibitors and works by interfering with the structure of DNA, leading to cell death.
Immunotherapy | Drugs in Phase II
Durvalumab is new drug being investigated for the treatment of myeloma. Durvalumab belongs to a class of drugs known as monoclonal antibodies and stimulates the immune system to attack myeloma cells by targeting a protein called PD-L1.
Immunotherapy | Drugs in Phase II
CC-220 is a new drug being tested for the treatment of myeloma. CC-220 is an immunomodulatory drug which like thalidomide, lenalidomide and pomalidomide targets a protein called cereblon. Cereblon has a number of functions and therefore inhibition of celebron causes myeloma cells to stop functioning properly leading to myeloma cell death.
Cell Signalling/Cycle | Drugs in Phase I
Buparlisib is a new oral drug being investigated as a treatment for myeloma. It belongs to a class of drug known as a phosphatidlyinositol 3-kinase (PI3 kinase) inhibitor and works by disrupting the cell signals that control the growth and survival of myeloma cells, causing them to die.
Cell Signalling/Cycle | Drugs in Phase II
DTP3 is a new drug being tested in myeloma. It belongs to a class of drugs which works by inhibiting the NF KB signalling pathway, thus preventing the growth and survival of myeloma cells.
Immunotherapy | Drugs in Phase II
GSK2857916 is a new drug being investigated as a treatment for myeloma. It consists of a chemotherapy drug attached to an antibody which targets a protein on myeloma cells. GSK2857916 targets a protein called B cell maturation antigen (BCMA). This type of drug is called an antibody-drug conjugate.
Other | Drugs in Phase I
Reolysin is a new treatment being investigated in myeloma and other cancers. It is as an oncolytic virus, a type of virus that preferentially infects and kills cancer cells.
Immunotherapy | Available Drugs
Thalidomide is a drug that is used as a treatment for myeloma. It belongs to a class of `drugs called immunomodulatory drugs (IMiDs).
Immunotherapy | Drugs in Phase III
Pembrolizumab is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs known as checkpoint inhibitors and targets the protein PD-1. PD-1 functions as checkpoint on the surface of cells to stop the immune system harming “healthy cells”. Myeloma cells express PD-1 so immune response to the myeloma cell is switched-off. Pembrolizumab therefore helps the immune system to recognise and destroy myeloma cells.
Immunotherapy | Available Drugs
Revlimid is a drug that is used as a treatment for myeloma. It belongs to a class of drugs called immunomodulatory drugs (IMiDs) and is a derivative of thalidomide.
Other | Drugs in Phase III
Selinexor, previously known as KPT-330, is the first in a new class of drugs being investigated as a treatment for myeloma. It belongs to a class of drug called selective inhibitor of nuclear export (SINE) and works by disrupting survival mechanisms in myeloma cells.
Immunotherapy | Available Drugs
Pomalidomide is a drug used as a treatment for myeloma. It is a derivative of thalidomide and belongs to a class of drugs called immunomodulatory drugs (IMiDs).
Other | Drugs in Phase III
Venetoclax (previously ABT-199) is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as BCL-2 inhibitors, which work by accelerating cancer cell death.
Other | Available Drugs
Dexamethasone is a steroid drug which is given alone or in combination with other drugs as a treatment for myeloma.
Other | Available Drugs
Prednisolone is a steroid drug which is given alone or in combination with other drugs as a treatment for myeloma.
Other | Available Drugs
Mozobil is a drug used to help mobilise stem cells from the bone marrow into the blood so that they can be harvested in preparation for high-dose therapy and stem cell transplantation.
Immunotherapy | Drugs in Phase III
Nivolumab is a new drug being tested as a treatment for myeloma and other blood cancers. It belongs to a class of drugs known as checkpoint inhibitors and targets the protein PD-1. PD-1 functions as checkpoint on the surface of cells to stop the immune system harming “healthy cells”. Myeloma cells express PD-1 so immune response to the myeloma cell is switched-off. Nivolumab, therefore, helps the immune system to recognise and destroy myeloma cells.
Immunotherapy | Drugs in Phase III
Isatuximab, previously known as SAR650984, is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as monoclonal antibodies and targets the protein CD38 found on the surface of myeloma cells.
Cell Signalling/Cycle | Drugs in Phase II
Vemurafenib is a drug being investigated as a treatment for myeloma and other cancer patients who specifically have the BRAF V600E mutation. It belongs to a class of drugs known as protein kinase inhibitors and specifically targets the B-RAF enzyme.
Epigenetic Drug | Drugs in Phase II
CHR 3996 is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
Other | Drugs in Phase II
Tosedostat is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as aminopeptidase inhibitors.
Proteasome Inhibitor | Available Drugs
Carfilzomib is a drug being used as a treatment for myeloma. It belongs to a class of drugs called proteasome inhibitors, similar way to Velcade, but is thought to be more potent with fewer associated side-effects.
Proteasome Inhibitor | Available Drugs
Velcade is a drug used as a treatment for myeloma. It belongs to a class of drugs called proteasome inhibitors and was the first of its type to be used in myeloma.
Chemotherapy | Available Drugs
Cyclophosphamide is a chemotherapy drug used as a treatment for myeloma and other cancers.
Chemotherapy | Available Drugs
Melphalan is a chemotherapy drug used as a treatment for myeloma and other cancers.
Chemotherapy | Available Drugs
Etoposide is a chemotherapy drug used as a treatment for myeloma and other cancers.
Chemotherapy | Available Drugs
Cisplatin is a chemotherapy drug used as a treatment for myeloma and other cancers.
Epigenetic Drug | Available Drugs
Panobinostat is a drug being used as a treatment for myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
Chemotherapy | Available Drugs
Doxorubicin is a chemotherapy drug used as a treatment for myeloma and other cancers.
Chemotherapy | Available Drugs
Bendamustine is a chemotherapy drug used as a treatment for myeloma and other cancers.
Immunotherapy | Drugs in Phase III
Elotuzumab is a monoclonal antibody. It works by attaching to a protein that is present on the surface of myeloma cells. Myeloma cells produce a protein called SLAM-7 which is present on the cell surface. attaches Elotuzumab to the SLAM-7 protein found on the surface of myeloma cells, which flags the cell, enabling the immune system to target and kill it. It has been approved for use in the US and EU in combination with lenalidomide and dexamethasone at second line but it is not currently available through the NHS in the UK.
Other | Drugs in Phase III
Plitidepsin is a novel anti-cancer drug of marine origin that is being investigated for as a treatment for myeloma.
Epigenetic Drug | Drugs in Phase III
Vorinostat is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
Immunotherapy | Available Drugs
Daratumumab is a new drug being used as a treatment for myeloma. It belongs to a class of drugs known as monoclonal antibodies and targets the protein CD38 found on the surface of myeloma cells. Daratumumab attaches to the CD38 leading to myeloma cell death by apoptosis or immune-mediated actions. Daratumumab has been approved for myeloma patients in England, Scotland and Wales as a 4th line treatment.
Proteasome Inhibitor | Available Drugs
Ixazomib is an oral proteasome inhibitor. It works by blocking the actions of proteasomes. Proteasomes are large molecules found in all cells of the body, and they are involved in the breakdown of damaged or unwanted proteins. Ixazomib temporarily blocks their function, stopping them from breaking down unwanted proteins. This causes proteins to build up to toxic levels, killing the cell. Myeloma cells rely more heavily on proteasomes than normal healthy cells; they are therefore much more sensitive to ixazomib. Its approved in combination with lenalidomide and dexamethasone in England and Wales as a 4th line treatment for myeloma patients.
Chemotherapy | Drugs in Phase III
Melflufen is a in active form of melphalan, in which melphalan is bound to a peptide (small protein). Melflufen targets myeloma cells using peptidases (enzymes which breakdown peptides) which are often found at higher concentrations in myeloma cells. The peptidases in the myeloma cells break up melflufen releasing active melphalan. The melphalan can then kill the myeloma cell. Melflufen is being investigated for the treatment of relapsed/refractory myeloma patients in a phase III trial in the UK.
Cell Signalling/Cycle | Drugs in Phase II
Filanesib, previously known as ARRY-520, is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as kinesin spindle inhibitors and inhibits cell division.
